Bitcoin price today: dips below $112k, near 6-wk low despite Fed cut bets
On May 22, 2025, Daniel G. Kaye, a director at CME Group Inc. (NASDAQ:CME), executed a sale of 500 shares of the company’s Class A common stock. The shares were sold at an average price of $282.42 per share, amounting to a total transaction value of $141,209. The transaction comes as CME Group, with a market capitalization of $102 billion, trades near its 52-week high of $286.48, having delivered an impressive 27% return over the past six months. InvestingPro analysis indicates the stock is currently trading above its Fair Value.
Following this transaction, Kaye’s direct ownership in CME Group stands at 3,668 shares. The sale was officially documented in a filing with the Securities and Exchange Commission. The company maintains a strong dividend track record, having raised its dividend for 6 consecutive years with a current yield of 3.83%. For deeper insights into insider trading patterns and 8 additional key insights about CME Group, check out the comprehensive research available on InvestingPro.
In other recent news, CME Group has been the focus of several analyst evaluations and shareholder activities. UBS reaffirmed its Buy rating on CME Group with a $305 price target, emphasizing the company’s robust market position and potential for growth through new product offerings. The firm also noted increased retail investor participation as a positive factor. In a separate development, Argus Research raised its price target to $308, maintaining a Buy rating, citing anticipated growth in contract volumes driven by current economic and geopolitical conditions. RBC Capital maintained its Sector Perform rating with a $269 target, highlighting CME Group’s ability to capture growth during market fluctuations and increased retail adoption of micro-futures.
Barclays (LON:BARC) adjusted its price target slightly higher to $283, maintaining an Equalweight rating, after CME Group’s earnings report met EPS expectations but fell short on revenue. The report noted record trading volumes attributed to heightened market volatility. Additionally, CME Group’s recent Annual Meeting of Shareholders saw the election of fourteen Equity Directors and the ratification of Ernst & Young LLP as the independent public accounting firm for 2025. The meeting also addressed a quorum issue for the election of Class B Directors, with certain directors continuing as "holdover" directors. These developments reflect CME Group’s strategic direction and ongoing adaptation to market conditions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.